Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o. — Clinical Trial Site

20 Registered trials

7 Currently recruiting

Organisation

Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.

Location

Tomaszow Mazowiecki, Poland

Identifier

ORG-100047774

Address

Ul. Jana Pawla II 35, 97-200, Poland

Departments

Centrum Diagnostyki i Terapii Onkologicznej Tomaszów Mazowiecki II-Szpital Pododdział Chemioterapii
Department of Chemotherapy
Department of Clinical Oncology
N/A
NA
Oddzial Chemioterapii
Oddzial Chemioterapii Jednodniowej
Oddzial Onkologii
Oddzial Onkologii Klinicznej
Oncology department
Pododdzial Chemioterapii
Pododdział Chemioterapii
Pododdział Chemioterapii i Oddział Chemioterapii Jednodniowej

Clinical trials at this site (20)

Search interface

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo… Recruiting

2025-522093-36-00 Cancer cachexia 10 2026-05-20
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy. (SOLSTICE… Recruiting

2024-516180-85-00 Metastatic colorectal cancer 5 2019-04-15
A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting

2023-507803-76-00 Peripheral T-Cell Lymphoma 10 2024-09-26
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting

2023-504888-16-00 Patients with Human Epidermal Growth Factor Receptor 2 9 2020-10-05
A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended

2023-506054-20-00 Adenocarcinoma of the biliary tract (intrahepatic or ex 5 2024-06-05
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended

2023-505928-59-00 Triple Negative or Hormone Receptor low/HER2-negative B 5 2024-04-15
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Ended

2024-512915-33-00 Metastatic Colorectal Cancer 5 2022-12-22
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended

2023-509513-36-00 Melanoma (Stage III and IV) 4 2021-03-24
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer) Ended

2023-506975-83-00 HER2-positive metastatic breast cancer (MBC) and early 5